Abstract
Background
Patients who experience an acute coronary syndrome (ACS) are at high risk of further cardiovascular events. Long-term treatment of cardiovascular risk factors, such as hyperlipidemia, is critical to prevent progression of coronary heart disease. However, many patients do not reach recommended target levels for low-density lipoprotein (LDL) cholesterol, despite receiving lipid-lowering therapy.
Objective
To obtain an insight into the current treatment situation for very high-risk patients after an initial ACS in Germany.
Methods
The multicenter HYDRA-ACS registry study was initiated to document the clinical characteristics of very high-risk patients with ACS and hyperlipidemia in clinical practice. In addition, lipid profiles, lipid-lowering therapy, and lipid target achievement during treatment were documented over 1 year.
Results
353 patients who were documented had a mean age of 57.3 years, mean body mass index was 28.6 kg/m2, and 73.4% were male; 52.4% had a family history of myocardial infarction (MI) and 32.6% a family history of coronary heart disease (CHD). Patients’ medical histories commonly included CHD (32.9%), percutaneous coronary intervention (PCI; 25.5%), and previous ACS (23.0%). Common comorbidities included hypertension (68.6%), diabetes (17.3%), heart failure (16.7%), and stable angina pectoris (15.9%).
The proportion of patients receiving lipid-lowering therapy increased from 65.7% at baseline to 100% at the 12-month follow-up (p < 0.0001). Substantial increases in use were seen for statins (85.0% vs. 36.5%, p = 0.0002) and cholesterol resorption inhibitors (32.9% vs. 8.6%, p = 0.0003). Use of combination therapy increased. The proportion of patients undertaking physical exercise increased (p < 0.0001), as did consumption of fruit and vegetables (p = 0.0222) and fish (p = 0.0162), while alcohol consumption decreased (p = 0.0019). Median LDL cholesterol level decreased significantly from baseline (87 vs. 166 mg/dL, p < 0.0001), and the proportion of patients with a level < 70 mg/dL increased (50.0% vs. 5.7%, p < 0.0001). Median HDL cholesterol increased (47 vs. 45 mg/dL, p = 0.0235) and median triglyceride level decreased (119 vs. 148 mg/dL, p = 0.0080). The proportion of patients receiving antihypertensive drugs and platelet aggregation inhibitors increased. The most frequent cardiovascular events during the 12-month follow-up were PCI (25.9%) and cardiac catheterization without PCI (12.9%); MI occurred in 2.4% of patients; no deaths were reported.
Conclusions
This study provides a contemporary picture of the treatment of hyperlipidemia after ACS in patients in Germany. Despite treatment with lipid-lowering therapy, many patients did not achieve recommended lipid targets by 12 months after an ACS event.
Graphical abstract
Similar content being viewed by others
Data availability statement
Aggregated data available upon reasonable request from the sponsor.
Clinical centers recruiting patients
Robert-Bosch-Krankenhaus, Kardiologie, Stuttgart; Klinikum Leverkusen, Leverkusen; Vivantes Klinikum Neukölln, Berlin; Jüdisches Krankenhaus Berlin, Berlin; MATERNUS-Klinik für Rehabilitation, Bad Oeynhausen; Krankenhaus Buchholz i.d.N., Buchholz; Kreisklinikum Siegen, Siegen; Dr Lauterbach Klinik, Bad Liebenstein; Schwarzwald Baar Klinikum, Villingen-Schwenningen; ELBLANDKLINIKUM Riesa, Riesa; Hermann-Josef-Krankenhaus, Erkelenz; DRK Kliniken Köpenick, Berlin; Klinikum Herford, Herford; Carl-von-Basedow-Klinikum Merseburg, Merseburg; Euregio-Klinik Nordhorn, Klinik für Kardiologie, Nordhorn; Ameos Klinikum Schönebeck, Schönebeck; Klinikum Coburg, II. Medizinische Klinik, Kardiologie, Coburg; Vivantes Klinikum Spandau Kardiologie, Berlin; St. Josefshospital, Cloppenburg; Kreiskrankenhaus Altötting, Med. Klinik I, Altötting; Ilm-Kreis-Kliniken, Arnstadt-Ilmenau gGmbH, Arnstadt; Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik I, Würzburg; Ev. Krankenhaus Bethesda, Mönchengladbach; Klinikum Worms Kardio/Angio, Worms.
References
WHO (2021) Cardiovascular disease fact sheet. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 14 Sept 2022
Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442
Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, Flather MD, Budaj A, Quill A, Gore JM et al (2007) Decline in rates of death and heart failure in acute coronary syndromes, 1999–2006. JAMA 297(17):1892–1900
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA et al (2020) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285(13):1711–1718
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278
Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) Heart Protection Study Collaborative G: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361(9374):2005–2016
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192
EUROASPIRE (1997) A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18(10):1569–1582
Kotseva K, Wood D, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A et al (2016) EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 23(6):636–648
Gitt AK, Junger C, Jannowitz C, Karmann B, Senges J, Bestehorn K (2011) Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry). Clin Res Cardiol 100(4):277–287
Gitt AK, Juenger C, Jannowitz C, Karmann B, Senges J, Bestehorn K (2009) Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil 16(4):438–444
Gitt AK, Drexel H, Feely J, Ferrieres J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T et al (2012) Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 19(2):221–230
Drexel H, Chazelle F, Fauer C, Lautsch D, Gitt AK (2011) Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - Results of the DYSlipidemia International Study (DYSIS). Wien Klin Wochenschr 123(19–20):611–617
European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E et al (2011) ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32(14):1769–1818
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR et al (2016) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058
Andre R, Bongard V, Elosua R, Kirchberger I, Farmakis D, Hakkinen U, Fusco D, Torre M, Garel P, Araujo C et al (2014) International differences in acute coronary syndrome patients’ baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study. Heart 100(15):1201–1207
Gitt AK, Rieber J, Hambrecht R, Brachmann J, Graf K, Horack M, Karmann B, Vyas A, Lautsch D, Ambegaonkar B et al (2018) Do acute coronary events affect lipid management and cholesterol goal attainment in Germany? Results from the Dyslipidemia International study II. Wien Klin Wochenschr 130(23–24):707–715
Schwaab B, Zeymer U, Jannowitz C, Pittrow D, Gitt A (2019) Improvement of low-density lipoprotein cholesterol target achievement rates through cardiac rehabilitation for patients after ST elevation myocardial infarction or non-ST elevation myocardial infarction in Germany: Results of the PATIENT CARE registry. Eur J Prev Cardiol 26(3):249–258
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM et al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–1722
Steffens D, Bramlage P, Scheeff C, Kasner M, Hassanein A, Friebel J, Rauch-Kröhnert U (2020) PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther 20(1):35–47
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C et al (2019) Effect of alirocumab on mortality after acute coronary syndromes. Circulation 140(2):103–112
Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K et al (2020) Cost-effectiveness of alirocumab in patients with acute coronary syndromes: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol 75(18):2297–2308
Landmesser U, Pirillo A, Farnier M, Jukema JW, Laufs U, Mach F, Masana L, Pedersen TR, Schiele F, Steg G et al (2020) Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS patient pathway project. Atheroscler Suppl 42:e49–e58
Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Keil U, Group ES (2009) EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 16(2):121–137
Tiffe T, Morbach C, Malsch C, Gelbrich G, Wahl V, Wagner M, Kotseva K, Wood D, Leyh R, Ertl G et al (2019) Physicians' lifestyle advice on primary and secondary cardiovascular disease prevention in Germany: a comparison between the STAAB cohort study and the German subset of EUROASPIRE IV. Eur J Prev Cardiol. https://doi.org/10.1177/2047487319838218
Claessen BE, Guedeney P, Gibson CM, Angiolillo DJ, Cao D, Lepor N, Mehran R (2020) Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc 9(24):e018897
Reiner Z, De Backer G, Fras Z, Kotseva K, Tokgozoglu L, Wood D, De Bacquer D, Investigators E (2016) Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries–findings from the EUROASPIRE IV survey. Atherosclerosis 246:243–250
Dykun I, Wiefhoff D, Totzeck M, Al-Rashid F, Janosi RA, Hendricks S, Rassaf T, Mahabadi AA (2020) Treatment patterns of lipid-lowering therapy in patients with coronary artery disease aged above and below 75 years: a retrospective cross-sectional study of 1500 patients in a tertiary care referral center in Germany. Drugs Aging 37(7):521–527
Schiele F, Farnier M, Krempf M, Bruckert E, Ferrieres J, French G (2018) A consensus statement on lipid management after acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 7(6):532–543
Wassmuth S, Rohe K, Noack F, Noutsias M, Treede H, Schlitt A (2019) Adherence to lipid-lowering therapy in patients with coronary heart disease from the state of Saxony-Anhalt, Germany. Vasc Health Risk Manag 15:477–483
Drexel H, Coats AJS, Spoletini I, Bilato C, Mollace V, Perrone Filardi P, Rosano GMC (2020) An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. Eur Heart J Cardiovasc Pharmacother 6(2):115–121
Acknowledgements
Dr. Alexandra Bernhardt, Dr. Christoph Claas, Jelena Wellter, Martin Horack, Christiane Lober and Tobias Goertz (all IHF), Sophie Möller, and Marmar Kabir-Ahmadi (both Sanofi)
Funding
This study was sponsored and funded by Sanofi-Aventis Deutschland.
Author information
Authors and Affiliations
Contributions
AKG, KPG, UL, WM, WDP and NM developed the concept of the current study. AKG, PB and WDP collated and interpreted all the data. AKG and PB wrote the first draft of the manuscript which all authors revised for important intellectual content. All authors gave final approval and agreed to be accountable for all aspects of work ensuring integrity and accuracy.
Corresponding author
Ethics declarations
Conflict of interest
AKG, KGP, UL, WM, B and NM have received research support and/or consulting honoraria from different makers of lipid-lowering drugs including Sanofi. PB received funding for drafting the first version of the manuscript from Sanofi. WDP is an employee of and is holding stock in Sanofi.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Gitt, A.K., Parhofer, K.G., Laufs, U. et al. Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany. Clin Res Cardiol 112, 299–311 (2023). https://doi.org/10.1007/s00392-022-02108-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-022-02108-w